Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Baseline Characteristics, Drug Exposure, and Outcomes in an Exploratory Analysis From ODYSSEY-HCM - PubMed
8 hours ago
- #mavacamten
- #hypertrophic cardiomyopathy
- #clinical trial
- The study is an exploratory analysis from the ODYSSEY-HCM trial, focusing on mavacamten in patients with nonobstructive hypertrophic cardiomyopathy.
- It reports on baseline characteristics, drug exposure levels, and clinical outcomes in this patient population.
- The trial was funded by Bristol Myers Squibb, and many authors disclosed financial relationships with BMS and other pharmaceutical companies.